Effects of Three Months Fingolimod Therapy on Heart Rate

Journal of Neuroimmune Pharmacology

Volumn 10, Issue 4, 2015, Pages 651-654

  Simula, Sakari ^a   Laitinen, Tomi ^b   Laitinen, Tiina M ^b   Tarkiainen, Tuula ^a   Hartikainen, Juha E K ^b   Hartikainen, Päivi ^b  

^a MIKKELI CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Disease modifying therapies; Fingolimod; Heart rate; Multiple sclerosis

Indexed keywords

FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; ELECTROCARDIOGRAPHY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEART RATE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; AMBULATORY MONITORING; DRUG EFFECTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

ADULT; ELECTROCARDIOGRAPHY; FEMALE; FINGOLIMOD HYDROCHLORIDE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MONITORING, AMBULATORY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 84948575488     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-015-9619-8     Document Type: Article

References (18)

1. Bonnemeier H, Richardt G, Potratz J et al (2003) Circadian profile of cardiac autonomic nervous modulation in healthy subjects: differing effects of aging and gender on heart rate variability. J Cardiovasc Electrophysiol 14:791–799
2. Brinkmann V (2007) Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115:84–105
3. Brinkmann V, Billich A, Baumruker T et al (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9:883–897
4. Calabresi PA, Radue EW, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Neurol 13:545–556
5. Camm J, Hla T, Bakshi R, Brinkkman V (2014) Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J 168:632–634
6. Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33:91–101
7. Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415
8. Kappos L, Radue EW, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401
9. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
10. Li X, Shaffer ML, Rodriguez-Colon S et al (2011) The circadian pattern of cardiac autonomic modulation in a middle-aged population. Clin Auton Res 3:143–150
11. Mandala S, Hajdu R, Bergstrom J et al (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346–349
12. Massberg S, von Andrian UH (2006) Fingolimod and sphingosine-1-phosphate-modifiers of lymphocyte migration. N Engl J Med 355:1088–1091
13. Oo L, Thangada S, Wu M-T et al (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteosomal degradation of the receptor. J Biol Chem 282:9082–9089
14. Pelletier D, Hafler DA (2012) Fingolimod for multiple sclerosis. N Engl J Med 366:339–347
15. Rossi S, Rocchi C, Studer V et al (2015) The autonomic balance predicts cardiac responses after the first dose of fingolimod. Mult Scler 21:206–216
16. Schmouder R, Hariry S, David OJ (2011) Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol 68:355–362
17. Sic H, Kraus H, Madl J et al (2014) Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis. J Clin Allergy Immunol 134:420–428
18. Viitasalo MT, Kala R, Eisalo A (1982) Ambulatory electrocardiographic recordings in endurance athletes. Br Heart J 47:213–220